Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000769993-25-000070
Filing Date
2025-02-10
Accepted
2025-02-10 17:28:45
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9622
2 POA13G-24683321_20250128.txt EX-99 5139
  Complete submission text file 0000769993-25-000070.txt   16843
Mailing Address 200 WEST STREET NEW YORK NY 10282
Business Address 200 WEST STREET NEW YORK NY 10282 212-902-1000
GOLDMAN SACHS GROUP INC (Filed by) CIK: 0000886982 (see all company filings)

EIN.: 134019460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)

Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Subject) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91921 | Film No.: 25606797
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)